In this decision-model analysis, the authors compared overall clinical efficacy and total cost of empiric treatment of hospitalized cellulitis patients prescribed linezolid and oxacillin or vancomycin. The authors hypothesized that, when used appropriately, empiric linezolid treatment is an effective, potentially cost-saving antibiotic compared with treatment initiated with oxacillin or vancomycin. Data on efficacy, duration of antibiotic treatment, and hospital stay for first-line treatment success were obtained from two clinical trials. Other medical resource use data were obtained from an expert panel of clinicians. US hospital direct medical costs were determined using standard costing techniques. Overall efficacy and total cost of treatment were estimated for combinations of the risk of being infected with methicillin-resistant pathogens. Sensitivity analyses were performed to test the impact of changes in major assumptions. Overall first-line efficacy is better for empiric treatment initiated with linezolid than with oxacillin or vancomycin across the spectrum of the risk of being infected with methicillin-resistant bacteria. The average total cost of treatment is lower for treatment initiated with linezolid than with vancomycin across the spectrum, or than with oxacillin when the risk of being infected with methicillin-resistant pathogens is 18.7% or higher. Linezolid appears to be at least as effective as vancomycin or oxacillin for empiric treatment of hospitalized cellulitis patients. Linezolid is likely to be less costly compared with vancomycin at all resistance rates and with oxacillin when the risk of infection with methicillin-resistant pathogens is greater than 18.7%, a resistance rate commonly seen in US hospitals.
INTRODUCTION
Cellulitis is one of the most common diffuse skin and skin structure infections that can affect any area of the body, most commonly the face or lower legs. It involves areas of tissue below the skin surface and often starts in an area of broken skin. Gram-positive bacteria, such as Group A streptococci and Staphylococcus aureus, are most commonly implicated in cellulitis. Gram-negative bacteria are rarely involved. [1] [2] [3] In the past 20 years, management of infections caused by S aureus has become increasingly difficult as the proportion of S aureus isolates found to be resistant to first-line antibiotics has increased significantly. According to the National Nosocomial Infections Surveillance (NNIS) data, the incidence of methicillinresistant S aureus (MRSA) as a proportion of all S aureus isolates in the United States increased from 2.1% in 1975 to 29% in 1991 and to 35% in 1996. 4 Apart from an overall increase in MRSA rates, considerable local variation in MRSA rates among hospitals (and among different units within hospitals) has been well documented. 5, 6 Even within a unit with low MRSA risk, patient history (previous hospitalization, previous exposure to antibiotics) and type of treatment received may still imply a high risk of MRSA infection. Unit or hospital prevalence of MRSA is only one important factor among many. 7 When causative pathogens are known, management choices are relatively clear. While penicillin is recommended for the management of methicillin-sensitive streptococcal cellulitis, dicloxacillin or oxacillin may be more appropriate because these antibiotics are better suited for infections caused by S aureus and streptococci. 3, 8, 9 These antibiotics are not effective against methicillin-resistant pathogens such as MRSA, for which vancomycin is usually the drug of choice in the United States. The wide spread of MRSA in the past two decades has significantly increased the empiric use of vancomycin in many institutions. However, vancomycin is not considered the best choice when the pathogens are methicillin susceptible. Thus, oxacillin, dicloxacillin, or vancomycin as initial empiric treatments-started depending on the relative risks of MRSA-may be suboptimal if initial suspicions prove incorrect. The initial choice of empiric treatment becomes more crucial when pathogens cannot be isolated from the majority of patients for indications such as cellulitis. In seriously ill patients, inadequate and inappropriate initial treatment has been shown to lead to higher mortality and morbidity. [10] [11] [12] For less severely ill patients, morbidity and economic implications still make the initial choices important. Other studies have demonstrated that clinical effectiveness of the initial antibiotic has the greatest impact on the total cost of care for infections, where high initial clinical effectiveness will result in fewer treatment failures and subsequently fewer and shorter hospitalizations. 13 With high resistance rates compounded by individual patient risk factors, empiric treatment with either oxacillin or vancomycin on the respective presumption of MSSA or MRSA may lead to suboptimal treatment of patients.
Linezolid is the first of a new class of antibiotics, oxazolidinones, which has activity against a broad spectrum of gram-positive bacteria, including MSSA and MRSA. Linezolid was first approved in the United States in April 2000 for the management of community-acquired pneumonia, hospital-acquired pneumonia, skin and soft tissue infections, and infections caused by MRSA or vancomycin-resistant enterococci (VRE). With its unique mechanism of action, it is not expected to develop cross-resistance with other available antibiotics. The efficacy of linezolid for skin and soft tissue infections has been shown to be comparable with that of oxacillin against MSSA 14 and of vancomycin against MRSA. 15, 16 Besides its intravenous formulation, linezolid is also available in oral form with 100% bioavailability, which allows patients to be discharged early from the hospital while continuing treatment on the same antibiotic in an oral formulation. This unique feature makes linezolid superior to vancomycin for managing MRSA infections. Study has shown that for skin and soft tissue infections, the median length of hospital stay (LOS) for patients treated with linezolid was 5 to 8 days shorter than for patients treated with vancomycin. 16 The objective of this study is to assess the clinical and economic consequences of using linezolid for the empiric treatment of cellulitis by comparing the overall first-line efficacy rates and total direct medical costs from US hospital perspective for hospitalized cellulitis patients initiated treatment with linezolid versus those initiated treatment with oxacillin or vancomycin. We hypothesize that because linezolid does not sacrifice efficacy in either MRSA or MSSA infections, whereas both comparators do in one of these pathogen types, linezolid may be a superior empiric treatment alternative from cost and first-line treatment efficacy perspectives. A clinical decision analysis model based on an appropriate-use principle was developed to estimate these efficacy and cost outcomes.
METHODS
A decision analytical model was developed to calculate the total direct medical cost of treatment of cellulitis among hospitalized patients in the United States. In the model, antibiotic treatment is initiated on an empiric basis under three alternative treatment scenarios: intravenous (IV) oxacillin (2 g every 6 hours with an option to switch to oral dicloxacillin 500 mg every 6 hours), IV vancomycin (1 g every 12 hours), or linezolid (600 mg every 12 hours, initiated IV with an option to switch to oral). At the same time, a specimen, if obtainable, is taken for a bacterial culture and sensitivity test (C&S). The initial antibiotic is continued or switched to a clinically appropriate alternative based on the C&S results and the appropriate-use principle, which is defined as (1) for treatment initiated with IV linezolid, switching to IV oxacillin if the pathogen is found to be methicillin-susceptible such as MSSA, or maintaining linezolid if the infection is found to be methicillin-resistant such as MRSA or when the pathogen remains unknown (specimen cannot be obtained for C&S or pathogen could not be determined from the C&S); (2) for treatment initiated with IV oxacillin, switching to vancomycin if the pathogen is found to be methicillin resistant, or maintaining oxacillin if the pathogen is found to be methicillin susceptible or when the pathogen remains unknown; or (3) for treatment initiated with IV vancomycin, switching to IV oxacillin if the pathogen is found to be methicillin susceptible, or maintaining vancomycin if the pathogen is found to be methicillin resistant or when the pathogen remains unknown (Table 1) . For those patients on IV linezolid or oxacillin, a switch to oral linezolid (from IV linezolid) or oral dicloxacillin (from oxacillin) was allowed when clinically appropriate. These three treatment options were chosen because of the availability of clinical data needed for the model, though we recognize that these treatment options may not be standard clinical practice in some institutions.
Model design
The model has three main branches, one for each of the three treatment options. Within each branch is embedded a decision tree based on the clinical pathway described in Table 2 . A schematic representation of the model used for this study is shown in Figure 1 . Costs of infections caused by non-gram-positive pathogens were not assessed in this model because the majority of cellulitis cases are caused by gram-positive pathogens, and the purpose of the model is to compare the cost of treatment across three gram-positive antibiotics-linezolid, vancomycin, and oxacillin-all not appropriate for use in managing non-gram-positive bacterial infections.
For each treatment arm, three clinical outcomes are modeled: success, failure due to lack of efficacy, and failure due to adverse events. Death as a possible outcome was not included in the model as patients rarely die of cellulitis, as indicated in the clinical trials. If first-line treatment fails, whether due to lack of efficacy or to adverse events, treatment is switched to an average second-line standard care treatment as suggested by our physician panels.
The time horizon of this model covered the period of treatment initiation in the hospital until no greater than three treatment switches. The same three clinical outcomes are modeled for the second-and third-line antibiotic treatments.
Model assumptions
The model is based on the following assumptions.
• Patients initiate antibiotic treatment in the hospital.
• Clinical success means improvement in, or complete recovery from, an infection. The clinical success rates used are the ones reported in the applicable clinical trials, and the average success rates of the patient populations in the clinical trials were used for methicillin-susceptible grampositive infections and methicillin-resistant staphylococci infections, respectively. 14, 15 • The clinical success rate for vancomycin in managing methicillin-susceptible gram-positive infections is equal to the clinical success rate for vancomycin in managing methicillin-resistant staphylococci infections as observed in comparative clinical trials. • Clinical failure means that a patient did not recover from the infection, experienced a worsening infection, or had an adverse event due to the infection or the treatment. In the model, treatment failure implies an entire new treatment course with a new antibiotic. • A specimen, if obtainable, is taken for C&S right before initiation of treatment, and the C&S results are returned from the laboratories to physicians after 2 days. Initial treatment success, failure, or adverse events are also observed after 2 days, as estimated from a survey among clinical experts (data not shown). Switch to appropriate antibiotic treatment occurs at this point. • Pathogen remains unknown means either the specimen cannot be obtained for C&S or a pathogen cannot be identified from the C&S. For patients whose pathogens remain unknown, the risk of the patients being infected with methicillinresistant pathogens is assumed to be equal to the proportion of patients infected with methicillinresistant pathogens among patients with known pathogens, and these patients' clinical efficacy and health care utilization (aside from first-line antibiotics) are estimated according to the presumed underlining pathogens. • Additional health care utilization for adverse events was assumed to be the same for methicillinresistant and methicillin-susceptible infections. • The base case rate of patients whose pathogens remain unknown is 80%, based on the data from a survey of 12 infectious disease specialists. Other evidence confirms this as a reasonable estimate. 17, 18 • Costs are evaluated up to three lines of treatment.
Though the existence of third-line treatment failures is possible (and probably highly costly), we lacked sufficient data to provide this extension to the model.
Data sources and collection
Three types of data were used for the model: probabilities of clinical events, data on health care utiliza-tion, and data on costs. The probabilities of clinical events were based on results from two clinical trials of linezolid (linezolid versus oxacillin for methicillinsusceptible gram-positive, including MSSA, infections, and linezolid versus vancomycin for methicillinresistant Staphylococcus species, mainly MRSA and MRSE, infections) and can be found in Table 2 . These trials were not designed to detect a difference in efficacy between the antibiotics but rather to demonstrate equivalent efficacy. Since we did not want to influence the modeling results by small, but not statistically significant, differences in the point clinical success rates between the antibiotics in each trial in favoring linezolid (93.5% for linezolid versus 88.7% for oxacillin in the methicillin-susceptible infections trial; 82.4% for linezolid versus 77.3% for vancomycin in the methicillin-resistant Staphylococcus species infections trial; see details below), we decided to use the average clinical success rates from the two trials: 91.1% for methicillin-susceptible pathogens and 79.85% for methicillin-resistant pathogens ( Table 2 ). The impact of using the point clinical success rates was tested in a sensitivity analysis. Estimates of LOS for patients treated successfully with first-line antibiotics were derived from the two clinical trials. Estimates for other forms of health care utilization consequent to treatment switches due to treatment failures were derived from the opinion of experts (a panel of infectious disease practicing physicians), as the number of patients in the trials experiencing these events was far too small to make any inferences for these events. The use of expert opinion, though not ideal, is necessary and appropriate when there is not sufficient trial data nor published literature available. 19, 20 Expert opinion was gathered using a modified Delphi method. [21] [22] [23] A panel consisting of five surgeons and five infectious disease specialists from the United States was interviewed during oneon-one interviews via telephone. After all experts were interviewed, data were summarized (means and ranges) and included in a second consensus round performed by mail. Questionnaires were developed to capture health resource utilization with the use of sample patient profiles representing cases along the alternative clinical pathways of the model. These questionnaires were validated prior to the expert interviews to ensure collection of complete and accurate health care utilization estimates.
Cost estimates for direct medical care were based on estimating the units of health care utilization and their respective costs, as described below. As such, instead of a single overall charge billed for total health care resource use, individual items of medical resource utilization were costed, and the total cost is the aggregate of all costed items. Costs were based on current costing data for US hospitals, including the price to the hospital of medications, procedures, consultations, and the hospital bed cost. Costs for home IV antibiotic administration were also included for those patients who were discharged while on IV antibiotic treatment, 24 since it can be assumed that these costs will be a burden to the hospital as well. Sensitivity analyses have been done with the home IV antibiotic treatment costs excluded. Unit costs are derived from average wholesale prices (AWP) for medication use (1999), CPT codes (1999), and Medicare payment amounts (ie, relative value units, 1998) for procedures. The average costs for hospital bed days were obtained from the 1997 MEDPAR data. For the main antibiotics used in this study (linezolid, oxacillin, and vancomycin), the direct prices (ie, from the manufacturer) were used. Although a typical US hospital does not pay for the cost of outpatient drugs after a patient is discharged from the hospital, the costs of a full course of the three initial antibiotics were included to reduce the underestimate of drug cost for discharged patients who continue their treatment on oral linezolid or dicloxacillin. Table 3 shows some of the principal cost and utilization parameters underlying the model. 
Data analysis
The model was built using Microsoft Excel 97 (Microsoft Corporation, Redmond, WA) and DATA (version 3.5.6, TreeAge software, Williamstown, MA). The primary endpoint of the model comparing linezolid versus oxacillin and vancomycin was the total average cost of management of cellulitis to the hospital. Additionally, the costs of major types of resources used (ie, antibiotics, comedications, consultations, procedures, and hospitalization costs) were also calculated separately for both treatment options. Total cost of treatment for an average patient was calculated using the fold-back method. No statistical testing was done; however, sensitivity analyses were performed to test the impact of (1) variations in the risk of infection with methicillin-resistant pathogens, (2) the percentage of patients (or the likelihood of a patient) whose pathogens remain unknown (could not obtain specimen for C&S or could not identify pathogens after C&S), (3) the first-line treatment success rate of oxacillin for infections caused by methicillin-resistant pathogens, and (4) the first-line success rates of all three comparator drugs (using point treatment success rates from the two trials) on the overall cost for each of the three treatment branches in the model. Figure 2 shows the overall first-line efficacy for each of the three treatment options assuming an 80% unknown pathogen, average treatment success rate between linezolid and oxacillin and dicloxacillin for methicillin-susceptible infections or between linezolid and vancomycin for methicillin-resistant infections, and 0% treatment success rate for oxacillin and dicloxacillin for methicillin-resistant infections. As can be seen, clinical efficacy for linezolid and vancomycin remains fairly constant independent of the risk of being infected by methicillin-resistant pathogens, while the clinical efficacy for oxacillin decreases when resistance risk increases. Across the resistance spectrum from 0% to 100%, linezolid shows better efficacy than vancomycin and oxacillin. Figure 3 shows the total cost of treatment for each of the three treatment options with the same assumptions as for Figure 2 . As shown in this figure, increasing the risk of being infected with methicillin-resistant pathogens resulted in an increase in the average cost per patient. The risk at which the cost of treatment initiated with linezolid equals the cost of treatment initiated with oxacillin is 18.7%. Treatment initiated with vancomycin is more expensive than treatment with linezolid across the full spectrum of the risk of being infected with methicillin-resistant pathogens.
RESULTS
We performed a sensitivity analysis to look at the impact the unknown pathogen rate had on the cost break-even point. At the 30% low rate of unknown pathogens, the cost break-even point between treatment initiated with linezolid and treatment initiated with oxacillin was 21.05% of the risk of infection with methicillin-resistant pathogens (as compared with 18.7% when the unknown pathogens is 80%), indicating that the percentage of unknown pathogens has only a small impact on the results.
The value of linezolid in empiric therapy is primarily through its avoidance of failure in the face of uncertainty of pathogenic resistance. This may be illustrated with an example where the model is run with 0% or 100% risk of methicillin-resistant infection as extreme cases (each with 0% unknown pathogens assumed). In the case of the risk to be 0%, the total average cost per patient whose treatment is initiated with linezolid was $4,370 compared with $4,163 for a patient treated with oxacillin and $4,180 for a patient treated with vancomycin. Because of the 0% unknown pathogens, after 2 days of empiric treatment, all patients are switched to or continue oxacillin, based on the appropriate-use principle, and the treatment costs are essentially the same for all patients after the initial 2 days. As expected, when all the pathogens are known to be methicillin susceptible, the efficacious drug with low acquisition cost, oxacillin, is a less expensive therapy than linezolid. At the other extreme, when the risk of being infected with methicillinresistant pathogens is 100%, total average cost per patient on linezolid was $11,267 compared with $11,627 for a patient treated with oxacillin and $11,645 for a patient treated with vancomycin. It is obvious that initiating treatment with oxacillin is inappropriate in this extreme case when the risk of a pathogen-resistant infection is 100%, and the results indicate that it is more costly. Interestingly, while vancomycin is less expensive in acquisition cost than linezolid and equally efficacious for methicillin-resistant infections per the assumption of using average treatment success rate, it is not least costly. This results from the oral form of linezolid allowing early discharge from the hospital.
The breakdown of total costs by type of resource utilization showed that the major cost drivers for all three treatments are cost of hospital stay and cost of antibiotics ( Fig. 4A and B) . Included in the cost of antibiotics are the antibiotics given as a second and third treatment option after failure of the first or second antibiotic. These figures show that antibiotic costs alone are highest in the linezolid arm, although antibiotic costs in the oxacillin arm increase rapidly as resistance risk increases. However, hospitalization costs are lowest in the linezolid arm, with oxacillin arm costs again increasing most rapidly as resistance risk increases.
One of the assumptions of the model was that the treatment success rate of oxacillin for methicillinresistant infections was 0%. We examined the impact of this assumption on total cost of treatment of the oxacillin empiric treatment arm by increasing this success rate from 0% to 10% and 30%. Table 4 shows the effects of these increases, while maintaining the rate of unknown pathogens at 80%. This change of oxacillin's efficacy rate had only a small impact on the total average cost of treatment and on the break-even point of the risk of being infected with methicillin-resistant pathogens, at which cost of treatment with linezolid equals cost of treatment with oxacillin.
Another sensitivity analysis was performed on the impact of averaging the clinical trial treatment success rates and the total average cost of care as distinguished from using each treatment arm's point estimate of treatment success rate. The point estimates for linezolid treatment success rates were higher than the average estimates from both trials for methicillinsusceptible gram-positive infections (93.5% versus 91.1%) and methicillin-resistant staphylococci infections (82.4% versus 79.9%; Table 2 ). In contrast, the point estimates of treatment success rates for oxacillin and vancomycin were lower than the average estimates (for oxacillin, 88.7% versus 91.1%; for vancomycin, 77.3% versus 79.9%). As would be expected from these data, results became more favorable to treatment initiated with linezolid for first-line overall efficacy and for total costs of treatment over the entire range of the risk of being infected with methicillin-resistant pathogens. Qualitative conclusions remained the same, though the break-even point at which total cost of treatment with linezolid equals total cost of treatment with oxacillin was lowered from 18.7% to 15.5% of the risk of being infected with methicillin-resistant pathogens. Again, linezolid total treatment costs were consistently lower than those of vancomycin when this assumption changed.
DISCUSSION
The increased resistance of pathogens against these antibiotics threatens the expectations of clinicians and patients for high clinical effectiveness of antibiotics. Factors most commonly associated with increased risk of infection by MRSA, a most common and important gram-positive pathogen, include long and repeated hospitalization and inappropriate use of ␤-lactam class of antibiotics. The decrease in antibiotic efficacy will lead to a higher likelihood of treatment failure, resulting in adverse health outcomes, more complicated treatment decisions, and higher costs of treatment. MRSA infection has been associated with increased mortality and results in longer hospital stays and increased cost of treatment. 25, 26 A recent study of 12 New York City hospitals found that the proportion of all bacterial infections attributable to MRSA ranged from 10% to 38% in these hospitals. 5 The risk of an MRSA infection can vary considerably between institutions and units within a hospital and by patient type. This variation can affect efficacy and costs of empiric treatment. Studies have shown that the costs associated with the management of MRSA are higher than those of management of methicillin-sensitive S aureus infections, with the increase ranging from $2,500 to $5,104. 26, 27 In a US university-based tertiary care center, a case-control study of primary nosocomial bloodstream infections found a nearly threefold increase in direct hospital costs due to MRSA infections (average $27,083 and a 12-day hospital stay) compared with those due to methicillin-sensitive S aureus infections (average $9,661 and a 4-day hospital stay). 28 While some of these costs may be due to greater patient severity with MRSA infections, at least part of this added cost may be explained by a lack of an oral treatment alternative for MRSA at the time these studies were conducted.
Shortsighted cost concerns that focus only on drug acquisition costs can be deleterious not only to patients' health but also to total costs of care. In this study, we compared the costs of empiric treatment of cellulitis using a new antibiotic, linezolid, with those of two antibiotics commonly used for this indication, oxacillin and vancomycin. Because linezolid is equal in efficacy to these treatments for MSSA and MRSA, while both comparators are not, treatment with linezolid was thought to be a superior empiric treatment alternative. Because it is difficult to conduct an empiric treatment trial-particularly for registration purposes-the total cost of empiric treatment was addressed in this analysis using a decision model.
Among the three antibiotics compared in this study, acquisition costs of linezolid regimens are higher than those of oxacillin and vancomycin. However, the economic evaluation of a drug depends not only on its acquisition cost but also on its clinical effectiveness and adverse event profile, the costs associated with preparation and administration, monitoring, the management of adverse events, and other medical resource use it may affect relative to standard therapy. 29 Linezolid's economic and efficacy advantage over oxacillin (and other first-line antibiotics for grampositive infections) results from its efficacy against pathogens resistant to these antibiotics, such as MRSA. As the proportion of patients infected with such resistant pathogens increases, these relatively less expensive first-line antibiotics tend to fail more often, increasing patient morbidity and resulting in higher costs of treatment. As this model shows, when the risk of being infected by methicillin-resistant pathogens increased to certain level, in this case to about 19%, we see the total cost of treatment of patients initiated with oxacillin becomes higher than the total cost of treatment of patients initiated with linezolid. While the model shows ultimately equal efficacy in all treatment arms because death as a possible outcome is not included in the model, the cure of patients initiated with linezolid is achieved more quickly since first-line treatment efficacy was superior with linezolid. Breakdown cost analysis showed that while the acquisition cost for oxacillin is lower than that for linezolid, the higher acquisition cost of linezolid is quickly offset by the oxacillin arm's increased cost of longer hospitalization associated with its treatment failure. Sensitivity analysis on changing the assumption of oxacillin's efficacy for methicillin-resistant pathogens to up to 30% indicated no substantive changes in conclusions (Table 4 ).
In contrast, linezolid's cost advantage over vancomycin results mainly from linezolid's shorter LOS because its oral formulation allows hospitalized patients to be discharged from the hospital sooner (thus reducing the cost associated with hospitalization) and continue their antibiotic treatment at home. 14 As the breakdown cost analysis showed, the higher acquisition cost of linezolid is offset by the shorter LOS associated with the drug across the full spectrum of the risk of infection with methicillin-resistant pathogens, making it a better choice economically for the management of methicillin-resistant gram-positive infections. Other possible clinical advantages of linezolid may also make it more desirable than vancomycin for methicillin-resistant gram-positive infections, including vancomycin's toxicity profile, the risk of vancomycin resistance seen in enterococci (VRE) and intermediate sensitivity seen in staphylococci (GISA), and the need for IV administration for vancomycin, which may contribute to catheter-related complications including secondary infections. However, comparison of these clinical aspects between linezolid and vancomycin is beyond the scope of this study.
Given the above considerations, the results of the analysis indicated that empiric linezolid treatment is appropriate clinically and economically if the risk of methicillin-resistant pathogens exceeds 18.7%, a risk level frequently encountered in US hospitals.
Some of the limitations for this study are worth noting. The first limitation is typical to decision tree models, which usually do not allow for statistical testing of the differences between comparators. We have tried to address this weakness by using sufficiently wide ranges of values when doing sensitivity analysis. The second limitation is the use of assumptions in the model. While these assumptions are needed because we could not obtain some of the input data for the model, some of the assumptions may have significant influence to the model results. To fully assess such influences, we have done extensive sensitivity analysis on the assumptions that we considered influential to the results. The third limitation pertains to the use of input data from a panel of experts. While this is considered the best and standard means to obtain the best possible estimates in the absence of input data, expert opinions are still subjective, and the variation could be large. The fourth limitation is the use of clinical trial data, which typically provide clinical efficacy instead of effectiveness; the latter is often more desirable for modeling the empiric use of antibiotics. Lastly, it should be noted that our experts did not mention home IV administration. Extensive use of home IV vancomycin could reduce the linezolid cost advantage. Prospective studies could provide important information for validating this study.
CONCLUSION
This study showed that under the appropriate-use principle, empiric treatment of cellulitis initiated with linezolid, though with higher drug acquisition cost, can still yield better clinical and economic outcomes than empiric treatment initiated with vancomycin across the full spectrum (0-100%) of risk of infection with methicillin-resistant gram-positive pathogens, and better outcomes than empiric treatment initiated with oxacillin, as long as the risk of infection with methicillin-resistant pathogen exceeds 18.7%. Linezolid's clinical advantage lies in its comparable efficacy with these two drugs, while its potential in cost saving is likely related to (1) its oral formulation, which may reduce LOS compared with vancomycin, or (2) its efficacy superiority to oxacillin's for methicillin-resistant pathogens and to vancomycin's for methicillinsensitive pathogens, which may reduce the costs associated with treatment failures.
